Brief: Nordic Nanovector: Updates On Several Programs

Thor Medical ASA

17/09/2019 06:07

Sept 17 (Reuters) - Nordic Nanovector ASA  NANOV.OL :
    * PIVOTAL PHASE 2B PARADIGME TRIAL OF BETALUTIN® IN ADVANCED
RECURRENT FOLLICULAR LYMPHOMA (FL) IS PROGRESSING WITH 83 SITES
IN 24 COUNTRIES OPEN FOR ENROLMENT AS OF SEPTEMBER 16TH, 2019
    * ARCHER-1 - 100% ORR (3/3 COMPLETE RESPONSE (CR)) IN FIRST
COHORT
OF PATIENTS IN A PHASE 1B STUDY OF BETALUTIN® + RITUXIMAB IN
RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
    * NOK 6 MILLION IN EUROSTARS FUNDING GRANTED FOR TAKING
CHIMERIC
ALPHA-PARTICLE EMITTING ANTI-CD37 RADIOIMMUNOCONJUGATE ALPHA37
THROUGH LAST STEP TOWARDS CLINICAL TESTING
    * SUPERIOR EFFICACY OF ALPHA37 WITH RESPECT TO MARKET
LEADING
IBRUTINIB HAS BEEN SHOWN IN AN IBRUTINIB-RESISTANT MOUSE MODEL
OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    * LYMRIT 37-01 (RELAPSED INHL) - MEDIAN DURATION OF RESPONSE
OF
13.6 MONTHS FOR ALL RESPONDERS AND 32.0 MONTHS FOR COMPLETE
RESPONDERS VERSUS 9.0 MONTHS AND 20.7 MONTHS RESPECTIVELY
REPORTED LAST DECEMBER AT ASH
    * CLINICAL RESULTS OBTAINED SO FAR WITH BETALUTIN®
DEMONSTRATE
THAT RATIONALE BEHIND ITS DESIGN FOR TREATMENT OF NON-HODGKIN'S
LYMPHOMA WAS RIGHT
    * WE DECIDED TOGETHER WITH OUR PARTNER HEIDELBERG PHARMA TO
DISCONTINUE DEVELOPMENT OF NNV014 (ANTI-CD37 ADC), AN EARLY
STAGE DISCOVERY PROJECT IN LEUKAEMIA

Source text for Eikon:  ID:nWkr4pLlJ7 
Further company coverage:  NANOV.OL 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))